Sangart Initiates Study Of Hemospan In Chronic Critical Limb Ischemia

Armen Hareyan's picture
Advertisement

Sangart has started testing its lead product, Hemospan, in a Phase II clinical study involving chronic critical limb ischemia (CCLI) patients.

Advertisement